MyoKardia Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,911.00
43,648.00
112,265.00
139,869.00
256,504.00
314,686
Total Accounts Receivable
-
-
-
45,000.00
1,013.00
-
Other Current Assets
232.00
430.00
1,282.00
1,394.00
1,876.00
4,760
Total Current Assets
2,143.00
44,078.00
113,547.00
186,263.00
259,393.00
319,446
Net Property, Plant & Equipment
2,432.00
2,423.00
2,744.00
2,758.00
3,147.00
5,138
Total Investments and Advances
-
-
-
12,002.00
19,900.00
80,148
Other Assets
128.00
388.00
289.00
283.00
368.00
2,521
Total Assets
4,703.00
46,889.00
116,580.00
201,306.00
282,808.00
407,253
Accounts Payable
1,239.00
886.00
2,143.00
1,798.00
2,301.00
Other Current Liabilities
1,029.00
16,844.00
19,832.00
31,190.00
38,571.00
Total Current Liabilities
2,268.00
17,730.00
21,975.00
32,988.00
40,872.00
Other Liabilities
294.00
14,477.00
732.00
22,936.00
202.00
Total Liabilities
2,562.00
32,207.00
22,707.00
55,924.00
41,074.00
Common Equity (Total)
17,247.00
36,906.00
93,873.00
145,382.00
241,734.00
Total Shareholders' Equity
2,141.00
14,682.00
93,873.00
145,382.00
241,734.00
Total Equity
2,141.00
14,682.00
93,873.00
145,382.00
241,734.00
Liabilities & Shareholders' Equity
4,703.00
46,889.00
116,580.00
201,306.00
282,808.00
Preferred Stock (Carrying Value)
19,388.00
51,588.00
-
-
-

About MyoKardia

View Profile
Address
333 Allerton Avenue
San Francisco California 94080
United States
Employees -
Website http://www.myokardia.com
Updated 07/08/2019
MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.